Study | N | TP | FN | TN | FP | Sensitivity% (CI) | Specificity% (CI) | PPV% (CI) | NPV% (CI) |
---|---|---|---|---|---|---|---|---|---|
Marcellin 2011 [60] | 79 | 39 | 1 | 38 | 1 | 97.5 (85.7–100) | 97.4 (82.4–99.4) | 97.5 (88.5–100) | 97.4 (92.5–100) |
Martinez de Tejada 2006 [52] | 34 | 20 | 0 | 13 | 1 | 100 (79.9–100) | 92.8 (64.2–99.6) | 95.2 (74.1–99.7) | 100 (71.7–100) |
Akercan 2005 [54] | 45 | 25 | 0 | 19 | 1 | 100 (83.4–100) | 95.0 (73.1–99.7) | 96.1 (78.4–99.8) | 100 (79.1–100) |
Erdermoglu 2004 [47] | 71 | 35 | 1 | 34 | 1 | 97.2 (83.8–99.8) | 97.1 (83.4–99.8) | 97.2 (83.8–99.8) | 97.1 (83.4–99,8) |
Darj 1998 [51] | 75 | 44 | 2 | 27 | 2 | 95.6 (84.0–99.2) | 93.1 (75.8–98.8) | 95.7 (84.0–99.2) | 93.1 (75.8–98.8) |
Gaucherand 1997 [53] | 69 | 34 | 1 | 34 | 0 | 97.1 (83.4–99.8) | 100 (87.4–99.8) | 100 (87.4–100) | 97.1 (83.4–99.8) |
Guibourdenche 1999 [48] | 30 | 15 | 0 | 14 | 1 | 100 (74.6–100) | 93.3 (66.0–99.7) | 93.8 (67.7–99.7) | 100 (73.2–100) |
Rutanen 1996 [12] | 130 | 55 | 0 | 71 | 4 | 100 (91.9–100) | 94.7 (86.2–98.3) | 93.2 (82.7–97.8) | 100 (93.6–100) |
Actim PROM® pooled | 533 | 267 | 5 | 250 | 11 | 98.2 (95.5–99.3) | 95.8 (92.4–97.8) | 96.0 (92.8–97.9) | 98.0 (95.2–99.3) |
Abdelazim 2012 [58] | 150 | 73 | 2 | 74 | 1 | 97.3 (89.8–99.5) | 98.7 (91.8–99.9) | 98.6 (91.7–99.9) | 97.4 (90.0–99.5) |
Marcellin 2011 [60] | 79 | 38 | 2 | 38 | 1 | 95.0 (82.4–99.4) | 94.8 (79.3–98.0) | 95.0 (84.7–100) | 94.8 (87.9–100) |
AmniSure® pooled | 229 | 111 | 4 | 112 | 2 | 96.5 (90.8–98.9) | 98.2 (93.2–99.7) | 98.2 (93.1–99.7) | 96.5 (90.9–98.9) |